Table 1. Patient demographic and clinical characteristics at baseline.
| Characteristic | Total population (n=1,312), n (%) |
|---|---|
| Age (years) | 49 [43–56] |
| Menstrual status | |
| Premenopausal | 450 (34.3) |
| Perimenopausal | 517 (39.4) |
| Postmenopausal | 345 (26.3) |
| Lesion side | |
| Left | 695 (53.0) |
| Right | 612 (46.6) |
| Bilateral | 1 (0.1) |
| Unknown | 4 (0.3) |
| cTNM staging† | |
| cT | |
| T1 | 130 (9.9) |
| T2 | 929 (70.8) |
| T3 | 247 (18.8) |
| Unknown | 6 (0.5) |
| cN | |
| N0 | 490 (37.3) |
| N1 | 601 (45.8) |
| N2 | 166 (12.7) |
| N3 | 54 (4.1) |
| Unknown | 1 (0.1) |
| cM | |
| M0 | 1,312 (100.0) |
| Histology (biopsy) | |
| Invasive ductal | 1,282 (97.7) |
| Invasive lobular | 15 (1.1) |
| Special types‡ | 10 (0.8) |
| Unknown | 5 (0.4) |
| Histological grade (biopsy) | |
| I | 34 (2.6) |
| II | 731 (55.8) |
| III | 163 (12.3) |
| Unknown | 384 (29.3) |
| ER status (biopsy) | |
| Positive | 795 (60.6) |
| Negative | 514 (39.2) |
| Unknown | 3 (0.2) |
| PR status (biopsy) | |
| Positive | 600 (45.7) |
| Negative | 706 (53.8) |
| Unknown | 6 (0.5) |
| HER2 (biopsy)§ | |
| Positive | 447 (34.1) |
| Negative | 657 (50.1) |
| Unknown | 208 (15.8) |
| Ki67 expression (biopsy)¶ | |
| High | 953 (72.6) |
| Low | 350 (26.7) |
| Unknown | 9 (0.7) |
| Regimen | |
| Chemotherapy | 1,285 (97.9) |
| Anthracycline- and taxane-based | 1,278 (99.5) |
| Anthracycline-based only | 1 (0.1) |
| Taxane-based only | 6 (0.4) |
| Chemotherapy + Anti-HER2 | 24 (1.8) |
| Endocrine therapy | 1 (0.1) |
| Unknown | 2 (0.2) |
| Course of chemotherapy (cycles) | |
| 2–4 | 1,213 (92.5) |
| 5–8 | 96 (7.3) |
| Unknown | 3 (0.2) |
Data are shown in median (IQR) or number of patients (%). ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2. †, the clinical staging of disease was documented according to the 8th edition of AJCC (American Joint Committee on Cancer) Cancer Staging Manual (20); ‡, special types in histology included mucinous carcinoma (n=6), spindle-cell carcinoma (n=1), carcinosarcoma (n=2), and tubular carcinoma (n=1); §, the status of HER2 was determined by either immunohistochemical analysis or fluorescence in situ hybridization (FISH); ¶, Ki67 expression was classified as high when ki67 index was no lower than 14%, else categorized as low.